Why Christopher Nolan’s IMAX record matters for investors
Christopher Nolan’s The Odyssey has become the highest grossing IMAX release on record, generating US$289 million in under a month and US$37 million on IMAX screens. This performance is drawing fresh attention to IMAX (IMAX) stock.
See our latest analysis for IMAX.
IMAX’s recent run on the back of The Odyssey comes after a strong year, with a 1-year total shareholder return of 97.46% and a 5-year total shareholder return of 250.10%. The 30-day share price return of 32.19% and 90-day share price return of 49.72% suggest momentum has recently accelerated despite a modest pullback over the past week.
If you are looking beyond IMAX and want more cinema and entertainment related ideas, this is a good moment to scan for other opportunities through the 19 top founder-led companies
IMAX looks like a strong business with record-breaking content partnerships and a global technology platform. After a near 50% gain in 90 days, the key question is whether that quality is already fully reflected in the price.
Most Popular Narrative: 1% Overvalued
The most followed IMAX narrative pegs fair value at $50.27, which sits just above the last close of $50.59. It frames the stock as roughly in line with its modeled worth while still demanding some strong execution to back that price.
Diversification of content offerings including local-language blockbusters, alternative content (concerts, live events), and deeper relationships with streaming and tech partners like Apple, Amazon, and Netflix is broadening IMAX's audience base and improving margin mix, contributing to higher contribution per screen and more resilient earnings.
Want to understand why this IMAX fair value sits so close to the market price? The narrative leans heavily on rising profitability, modest revenue expansion and a richer earnings multiple tied to premium content. Curious which specific growth and margin assumptions have to hold up for that to work.
Result: Fair Value of $50.27 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, IMAX still faces real pressure if blockbuster output softens, or if competing premium formats and at home options pull audiences away from its screens.
Find out about the key risks to this IMAX narrative.
Another View on IMAX’s Valuation
The main narrative puts IMAX close to fair value at about $50.27, just under the recent $50.59 share price. Our DCF model tells a very different story. It points to a future cash flow value of $83.12, which implies the stock trades at a large discount. Which set of assumptions feels more realistic to you?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IMAX for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The mixed signals around IMAX’s valuation and business momentum make this a good moment to look closer at the underlying data yourself. To see how the potential upside compares with the issues investors are watching, review the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond IMAX?
If IMAX has caught your attention, do not stop there. This is a good time to widen your watchlist and compare it with other focused opportunities.
- Target potential mispricings by scanning 51 high quality undervalued stocks that pair solid fundamentals with what may be attractive entry points.
- Prioritise resilience by reviewing 83 resilient stocks with low risk scores that score well on stability and smaller drawdown potential.
- Hunt for future standouts using the screener containing 21 high quality undiscovered gems before they appear on every investor’s radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com